

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form S-8

BIOMARIN PHARMACEUTICAL INC  
Form S-8  
April 02, 2002

As filed with the Securities and Exchange Commission on April 2, 2002  
Registration No. 333-\_\_\_\_\_

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM S-8  
REGISTRATION STATEMENT UNDER  
THE SECURITIES ACT OF 1933

BIOMARIN PHARMACEUTICAL INC.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of  
Incorporation or Organization)

68-0397820  
(I.R.S. Employer  
Identification No.)

371 Bel Marin Keys Boulevard, Suite 210  
Novato, California 94949  
(Address of Principal Executive Offices)

1997 STOCK PLAN, AS AMENDED  
1998 DIRECTOR OPTION PLAN  
1998 EMPLOYEE STOCK PURCHASE PLAN  
(Full title of the Plans)

Fredric D. Price  
Chairman and Chief Executive Officer  
371 Bel Marin Keys Boulevard, Suite 210  
Novato, California 94949  
(Name and Address of Agent For Service)

(415) 884-6700  
(Telephone Number, Including Area Code, of Agent for Service)

Copies to:  
Siobhan McBreen Burke, Esq.  
Paul, Hastings, Janofsky & Walker LLP  
555 South Flower Street, 23rd Floor  
Los Angeles, CA 90071-2371  
(213) 683-6000

CALCULATION OF REGISTRATION FEE

Title Of Securities To Be Registered	Amount To Be Registered (1)	Proposed Maximum Offering Price Per Share (2)	Proposed Aggregate Price
--------------------------------------	-----------------------------	---	--------------------------

Common Stock, \$0.001 par value,  
issuable pursuant to the 1997 Stock

**Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form S-8**

Plan, as amended.	5,917,229	\$9.67	\$57,219,0
=====			
-----			
Common Stock, \$0.001 par value, issuable pursuant to the 1998 Director Option Plan.	400,000	\$9.67	\$3,868,0
=====			
-----			
Common Stock, \$0.001 par value, issuable pursuant to the 1998 Employee Stock Purchase Plan.	400,000	\$9.67	\$3,868,0
=====			

- (1) Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock which become issuable under each of the 1997 Stock Plan, the 1998 Director Option Plan and the 1998 Employee Stock Purchase Plan, by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of BioMarin Pharmaceutical Inc. Common Stock.
- (2) Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rules 457(c) and (h) under the Securities Act, on the basis of the average of high and low sale prices for a share of common stock of BioMarin Pharmaceutical Inc. (BMRN) as reported on the Nasdaq National Market on April 1, 2002.

PART I

STATEMENT UNDER GENERAL INSTRUCTION E.  
REGISTRATION OF ADDITIONAL SECURITIES

The shares covered by this Registration Statement represent additional shares of the Registrant's Common Stock that have become available for issuance under the BioMarin Pharmaceutical Inc. 1997 Stock Plan, as amended, the 1998 Director Option Plan and the 1998 Employee Stock Purchase Plan (the "Stock Plans") as a result of an "evergreen provision" of each of the Stock Plans which automatically increase the number of shares authorized for issuance thereunder on the first day of each fiscal year. Since adoption, the evergreen provision, the number of shares available for issuance under the Stock Plans has increased from 5,694,259 to 12,411,488. Unless otherwise noted herein, the contents of the Registrant's Form S-8 Registration Statement (File No. 333-84787) relating to the Stock Plans are incorporated by reference into this Registration Statement.

PART II

Item 8. Exhibits

Exhibit	Description
-----	-----

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form S-8

- 5.1 Opinion of Paul, Hastings, Janofsky & Walker LLP.  
23.1 Consent of Arthur Andersen LLP, Independent Auditors.  
23.2 Consent of Paul, Hastings, Janofsky & Walker LLP (included in Exhibit 5.1).  
24.1 Power of Attorney (contained on the signature page).

### SIGNATURES1

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Novato, State of California, on March 29, 2002.

BIOMARIN PHARMACEUTICAL INC.

By: /s/ Fredric D. Price

-----  
Name: Fredric D. Price  
Title: Chairman, Chief Executive  
Officer and Director  
(Principal Executive  
Officer)

### POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Fredric D. Price and Emil D. Kakkis, M.D., Ph.D. as such person's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and dates indicated.

Signatures	Title	Date
/s/ Fredric D. Price ----- Fredric D. Price	Chairman, Chief Executive Officer and Director (Principal Executive Officer)	March 29, 2002
/s/ Kim Tsuchimoto-Evans ----- Kim Tsuchimoto-Evans	Vice President, Controller (Principal Financial and Accounting Officer)	March 29, 2002
/s/ Grant W. Denison, Jr. -----	Director	March 29, 2002

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form S-8

Grant W. Denison, Jr.

/s/ Phyllis I. Gardner      Director      March 29, 2002  
-----

Phyllis I. Gardner, M.D.

/s/ Erich Sager      Director      March 29, 2002  
-----

Erich Sager

/s/ Gwynn R. Williams      Director      March 29, 2002  
-----

Gwynn R. Williams

2

INDEX TO EXHIBITS

Exhibit -----	Description -----
5.1	Opinion of Paul, Hastings, Janofsky & Walker LLP.
23.1	Consent of Arthur Andersen LLP, Independent Auditors.
23.2	Consent of Paul, Hastings, Janofsky & Walker LLP (included in Exhibit 5.1).
24.1	Power of Attorney (contained on the signature page).

3

Exhibit 5.1

OPINION OF PAUL, HASTINGS, JANOFSKY & WALKER LLP

April 1, 2002

BioMarin Pharmaceutical Inc.  
371 Bel Marin Keys Boulevard, Suite 210  
Navato, California 94949

Ladies and Gentlemen:

We are furnishing this opinion of counsel to BioMarin Pharmaceutical Inc., a Delaware corporation (the "Company"), for filing as Exhibit 5.1 to the Registration Statement on Form S-8 (the "Registration Statement") to be filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended, relating to the issuance and sale by the Company of up to 6,717,229 shares (the "Shares") of its Common Stock, par value \$.001 per share ("Common Stock"), pursuant to the Company's 1997 Stock Plan, the Company's 1998 Director Option Plan and the Company's 1998 Employee Stock Purchase Plan as amended (as each may have been so amended, the "Plans").

We have examined the Certificate of Incorporation and Bylaws, each as

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form S-8

amended to date, of the Company, and the originals, or copies certified or otherwise identified, of records of corporate action of the Company as furnished to us by the Company, certificates of public officials and of representatives of the Company, and such other instruments and documents as we deemed necessary, as a basis for the opinions hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all corporate records and other documents submitted to us, the conformity to original documents submitted to us as certified or photostatic copies and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof. We have also assumed that, at the time the Shares are issued, the Company will have sufficient authorized and unissued shares of Common Stock.

Based upon our examination as aforesaid, and in reliance upon our examination of such questions of law as we deem relevant under the circumstances, we are of the opinion that the Shares, when purchased and issued as described in the Registration Statement and in accordance with the Plans (including the receipt of the full purchase price therefor), will be validly issued, fully paid and nonassessable.

We express no opinion with respect to the applicability or effect of the laws of any jurisdiction other than the Delaware General Corporation Law, as in effect as of the date hereof.

We hereby consent to the filing of this opinion of counsel as Exhibit 5.1 to the Registration Statement.

Very truly yours,

/s/ Paul, Hastings, Janofsky & Walker LLP

Exhibit 23.1

### CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

We consent to the incorporation by reference in this Registration Statement on Form S-8 pertaining to the (i) 1997 Stock Plan, as amended; (ii) 1998 Director Option Plan; and (iii) 1998 Employee Stock Purchase Plan of BioMarin Pharmaceutical Inc., of our report dated February 21, 2002, with respect to the financial statements of BioMarin Pharmaceutical Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2001, filed with the Securities and Exchange Commission.

/s/ Arthur Andersen LLP

San Francisco, California  
March 28, 2002

